Controversies in contraception

Current Opinion in Pediatrics

Volumn 20, Issue 4, 2008, Pages 383-389

  Pitts, Sarah A B ^a   Emans, S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adolescents; Bone health; Contraception; Emergency contraception

Indexed keywords

CONTRACEPTIVE AGENT; ETHINYLESTRADIOL PLUS NORELGESTROMIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PLACEBO;

BONE; BONE DENSITY; CLINICAL TRIAL; DRUG CONTRAINDICATION; EMERGENCY CONTRACEPTION; FRACTURE; HORMONAL CONTRACEPTION; HUMAN; HYPERTENSION; INTRAUTERINE CONTRACEPTIVE DEVICE; MIGRAINE; OBESITY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CONTRACEPTION; DRUG EFFECT; FEMALE; METHODOLOGY;

ADOLESCENT; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; HYPERTENSION; MEDROXYPROGESTERONE 17-ACETATE; MIGRAINE DISORDERS; OBESITY; OSTEOPOROSIS; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 52449088247     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328305e13f     Document Type: Review

References (45)

1. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and2001. Perspect Sex Reprod Health 2006;38:90-96.
2. Santelli JS, Morrow B, Anderson JE, et al. Contraceptive use and pregnancy risk among U.S. high school students, 1991-2003. Perspect Sex Reprod Health 2006; 38:106-111.
3. Abma JC, Martinez GM, Mosher WD, et al. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002. Vital Health Stat 2004; 24:1 -48.
4. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization; 2004. pp. 1-186. Available from: http://www.who.int/reproductive-health/publications/mec/.
5. Stanback J, Katz K. Methodological quality of WHO medical eligibility criteria for contraceptive use. Contraception 2002; 66:1 -5.
6. Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000; 61:77-82.
7. Harel Z, Gold M, Cromer B, et al. Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markers. J Adolesc Health 2007; 40:44-53.
8. Hartard M, Kleinmond C, Wiseman M, et al. Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone 2007; 40:444-450.
9. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception 2006; 73:445-469.
10. Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents-the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 2006; 39:296-301.
11. Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005; 159: 139-144.
12. Beksinska ME, Kleinschmidt I, Smit JA, et al. Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception. Contraception 2007; 75:438-443.
13. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 2004; 35:434-441.
14. Cromer BA, LazebnikR, Rome E, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 2005; 192:42-47.
15. Scholes D, LaCroix AZ, Ichikawa LE, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002; 13:581 -587.
16. d'ArcanguesC. WHO statement on hormonal contraception and bone health. Contraception 2006; 73:443-444.
17. Hartard M, Kleinmond C, Luppa P, et al. Comparison of the skeletal effects of the progestogens desogestrel and levonorgestrel in oral contraceptive preparations in young women: controlled, open, partly randomized investigation over 13 cycles. Contraception 2006; 74:367-375.
18. Sowers MF, Scholl T, Harris L, et al. Bone loss in adolescent and adult pregnant women. Obstet Gynecol 2000; 96:189-193.
19. Miglioli L, Costa-Paiva L, de Lourenco LS, et al. The association of pregnancy history with areal and volumetric bone mineral density in adolescence. Osteoporos Int 2007; 18:101 -108.
20. Loder EW, Buse DC, Golub JR. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache 2005; 45:224-231.
21. Etminan M, Takkouche B, Isorna FC, et al. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005; 330:63.
22. Evans RW, Becker WJ. Migraine and oral contraceptives. Headache 2006; 46:328-331.
23. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527-1535.
24. Mishell DR, Shulman LP. Venous thromboembolism and cardiovascular disease: hormonal contraception. Dialogues Contracept 2007; 11:5-7.
25. Burkman RT, Grimes DA, Mishell DR,et al. Benefits of contraception to women's health: an evidence-based perspective. Dialogues Contracept 2006; 10:1 -4.
26. Speroff L, Kaunitz A. Contraception for the women with medical problems. Dialogues Contracept 2006;10:1-8. Available from: http://www.usc.edu/ schools/medicine/education/continuing-education/selfstudy.html.
27. Cole JA, Norman H, Doherty M, et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109:339-346.
28. Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006; 73:223-228.
29. Jick S, Kaye JA, Li L, et al. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2007; 76:4-7.
30. U.S. FDA. Ortho Evra (norelgestromin/ethinyl estradiol) Information. 2008. Available from: http://www.fda.gov/cder/drug/infopage/orthoevra.default. htm.
31. Atthobari J, Gansevoort RT, Visser ST, et al. The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate. Br J Clin Pharmacol 2007; 63:224-231.
32. Curtis KM, Mohllajee AP, Martins SL, et al. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception 2006; 73:179-188.
33. Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev (Online) 2006;CD003987.
34. Bonny AE, Ziegler J, Harvey R, et al. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med 2006; 160:40-45.
35. Westhoff CL. Contraception and obesity: effectiveness. Dialogues Contracept 2007; 11:8-9.
36. Holt VL, Scholes D, Wicklund KG, et al. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105:46-52.
37. Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol 2007; 166:1306-1311.
38. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77:S13-S18.
39. Westhoff CL, Anderson FD. Seasonale (30 jxg of ethinyl estradiol/150 jxg of levonorgestrel) extended-regimen oral contraceptive: efficacy and cycle control by body weight [abstract]. Contraception 2006; 74:181 -182.
40. Kripke C. Advance provision for emergency oral contraception. Am Fam Physician 2007; 76:654.
41. Walsh TL, Frezieres RG. Patterns of emergency contraception use by age and ethnicity from a randomized trial comparing advance provision and information only. Contraception 2006; 74:110-117.
42. do Nascimento JA, Seppala M, Perdigao A, et al. In vivo assessment of the human sperm acrosome reaction and the expression of glycodelin-A in human endometrium after levonorgestrel-emergency contraceptive pill administration. Hum Reprod 2007; 22:2190-2195.
43. Novikova N, Weisberg E, Stanczyk FZ, et al. Effectiveness of levonorgestrel emergency contraception given before or after ovulation: a pilot study. Contraception 2007; 75:112-118.
44. Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol 2007; 196:412.e411 -416 (discussion 412.e416-417).
45. Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007; 76:267-272.